Discussing the upcoming Supreme Court oral arguments in Amgen v Sanofi, Washington, DC Principal Nick Matich highlighted that the decision to hear the case could be one of the biggest IP developments this year, particularly given the Supreme Court’s decision to grant the petition against the recommendation of the government. Specifically, he noted that a decision will be a substantial development for the patent act next year and it “will be important to see how broadly the court writes its opinion to see how it may affect other areas of technology.” You can read the full article here.
